Adagen

This page contains recent news articles, when available, and an overview of Adagen but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.

Enzon Sets Special Meeting of Stockholders (NASDAQ:ENZN)  -  ‎Dec 23, 2009‎
...sales above a 2009 baseline amount from Enzon's four marketed specialty pharmaceutical products (Oncaspar, DepoCyt, Abelcet and Adagen) through 2014. ... FavStocks (blog)

Enzon Agrees To Sell Specialty-Drug Business For Up To $327M  -  ‎Nov 9, 2009‎
Enzon's specialty pharmaceutical business includes Oncaspar for leukemia, Adagen for immunodeficiency disease, DepoCyt for a type of meningitis and Abelcet ... Wall Street Journal

Enzon Reports Third Quarter 2009 Results  -  ‎Nov 3, 2009‎
The Company filed the Investigational New Drug (IND) Application with the FDA for the next-generation Adagen program early November. ... Reuters

Baupost Initiates Enzon Position, Ups ViaSat Stake  -  ‎Nov 11, 2009‎
The Company has a portfolio of four marketed products: Oncaspar, DepoCyt, Abelcet and Adagen. Enzon's drug development programs utilize several approaches, ... Seeking Alpha (blog)

Sigma-Tau buys specialty pharmaceuticals from Enzon  -  ‎Nov 12, 2009‎
Enzon's specialty pharmaceutical business includes four marketed products: Abelcet, an antifungal amphotericin B liposomal injection, Adagen, ... European Biotechnology News

BioWatch: Deal fits Sigma-Tau's focus on rare diseases  -  ‎Nov 12, 2009‎
Sigma-Tau will distribute the drugs — Enzon's only products on the market — in the US They are Oncaspar, a leukemia treatment; Adagen, a treatment for ... Business Gazette

Zacks Analyst Blog Highlights: Enzon, Merck, OSI Pharmaceuticals, Pfizer and ...  -  ‎Nov 11, 2009‎
...infection related to cancer and Adagen used to treat severe combined immunodeficiency disease (SCID), commonly known as the "bubble boy" disease. ... Zacks.com

Enzon to sell specialty pharmaceutical business to Sigma-Tau  -  ‎Nov 11, 2009‎
Enzon's specialty pharmaceutical business includes four marketed products: Oncaspar, Adagen, DepoCyt, and Abelcet, as well as the manufacturing facility in ... Trading Markets (press release)

Enzon Pharmaceuticals, Inc. - Pharmaceuticals & Healthcare - Deals and ...  -  ‎Nov 9, 2009‎
The product portfolio of the company includes Oncaspar, Depocyt, Abelcet and Adagen. The company uses its proprietry technologies including PEGylation and ... PR-Inside.com (Pressemitteilung)

Sigma-Tau, shopping negli Usa  -  ‎Nov 9, 2009‎
Il ramo d'azienda ceduto a sigma-tau da Enzon comprende quattro prodotti identificati dai seguenti marchi: Oncaspar, Adagen, DepoCyt e Abelcet, ... Il Sole 24 Ore

Enzon将以3亿美元出售特�?�?�业务  -  ‎Nov 9, 2009‎
Sigma-tau将�?收购的特�?�?�物包括抗癌�?�Oncaspar�?霉�?�感染治疗�?�物Abelcet�?脑膜炎�?�物DepoCyt，以�?�Adagen，�?�者被用于治疗严�?�?��?��?疫缺陷(severe combined ... 新浪网

FARMACI: DOMPE', IMPORTANTE ACQUISIZIONE DI ENZON DA SIGMA TAU  -  ‎Nov 12, 2009‎
...(AGI) - Roma, 12 nov. - "Esprimo forte apprezzamento per l'acquisizione della Divisione Specialty Care di Enzon Pharmaceuticals che sara' completata dopo ... AGI - Agenzia Giornalistica Italia

Disclaimer:

Contact a physician with regard to health concerns. Email requests for further health information will be discarded.

The materials contained on this Web site are for informational purposes only and do not constitute health or medical advice. Use of information on this site does not create or constitute any kind of agreement or contract between you and the owners or users of this site, the owners of the servers upon which it is housed, or anyone else who is in any way connected with this site.

Many links on cancernewsnetwork.org lead to other sites. cancernewsnetwork.org does not sponsor, endorse or otherwise approve of the materials appearing in such sites. Nor is CancerNewsNetwork.org responsible for dead or misdirected links.

IF YOU NEED A LINK OR TEXT REMOVED FROM THIS PAGE PLEASE CONTACT cancernewsnetwork (at) live.com.
We will do our best to accommodate your request.